Over a thousand attendees will gather at TCF ‘25 to explore Generative AI and other next-gen technologies transforming bankingGRAND-LANCY, Switzerland, May 08, 2025 (GLOBE NEWSWIRE) -- Temenos (SIX: TEMN), a global leader in banking technology, today announced that over a thousand global banking industry representatives will come together at the Temenos Community Forum (TCF) in Madrid, May 20-22, to explore transformative technologies shaping the future of banking. Registration for the event is open and an ...

Core Insights - BioPorto A/S reported continued progress on key strategic milestones in Q1 2025, maintaining revenue guidance for the year [1][2] - The company experienced a 19% decrease in revenue compared to Q1 2024, totaling DKK 7.7 million, primarily due to a shift in timing of bulk orders [5][7] - Adjusted EBITDA loss increased by 83% to DKK 28.1 million, driven by higher costs associated with clinical studies [5][7] Financial Performance - Revenue for Q1 2025 was DKK 7.7 million, down from DKK 9.5 million in Q1 2024, reflecting a 19% decline [5][7] - The adjusted EBITDA loss for Q1 2025 was DKK 28.1 million, compared to DKK 15.3 million in the same period last year, marking an 83% increase [5][7] - Full-year revenue guidance for 2025 remains at DKK 45-60 million, with expectations of back-end loaded sales [7] Sales and Market Developments - NGAL Research Use Only (RUO) sales in the U.S. grew by 20% compared to Q1 2024, despite a 25% decline in total NGAL sales due to decreased sales in the rest of the world [6][7] - Preparations for the commercial launch of ProNephro AKI NGAL for pediatric use are on track, with faster-than-expected patient enrollment in the adult clinical study [6][7] - The company aims to submit to the FDA by the end of 2026 for the ProNephro AKI (NGAL) study [6][7] Capital and Investment - On April 16, 2025, BioPorto completed a successful issuance of 25,000,000 new shares, raising gross proceeds of DKK 33.5 million [4][8] - The funding round attracted strong commitments from both existing shareholders and new investors [4]

Core Insights - A.P. Møller - Mærsk A/S reported strong results for Q1 2025 compared to the same quarter last year, attributed to operational efficiency and a favorable global economy [1] - The company is focusing on enhancing customer support through its reliable ocean network and logistics services amidst rising trade tensions and uncertainty [1] - A.P. Møller - Mærsk A/S is committed to automation and cost management to maintain competitiveness and is confident in meeting its previously communicated guidance [1] Financial Performance - The interim report indicates a positive performance in Q1 2025, reflecting the company's ability to adapt to market conditions [1] - Specific financial metrics were not detailed in the provided text, but the overall sentiment suggests a robust financial standing [1] Strategic Focus - The company emphasizes the importance of operational efficiency and customer service in navigating current global supply chain challenges [1] - A.P. Møller - Mærsk A/S is actively working on automation and cost management strategies to prepare for future market conditions [1]

Core Insights - The company reported strong sales growth and earnings in the first quarter, with all four sales areas achieving double-digit growth [1][3] - Growth was primarily driven by strong innovation in emerging markets and continued demand for solutions in developed markets [1] - The company confirmed its full-year outlook, expecting solid demand and agility in response to dynamic market conditions [1] Financial Performance - Organic sales growth was 11%, with approximately 1 percentage point attributed to price increases [3] - Emerging markets experienced organic sales growth of 15%, while developed markets saw growth of 9% [3] - Adjusted EBITDA margin improved to 38.3%, an increase of 310 basis points [3] - Adjusted net profit rose by 27% [3] - Net Interest-Bearing Debt (NIBD) to EBITDA ratio stood at 1.1x [3] Strategic Developments - The company announced plans to acquire dsm-firmenich's part of the feed enzyme alliance for EUR 1.5 billion, expected to close in the second quarter [3] - Andrew Taylor was appointed as the new EVP of Food & Beverages, set to join the company by September 1, 2025 [3] Outlook - The company maintained its 2025 outlook, projecting organic sales growth of 5-8% (6-9% excluding exits from certain countries) and an adjusted EBITDA margin between 37-38%, despite facing currency headwinds [3]

Core Insights - Nykredit reported a satisfactory interim profit after tax of DKK 3,000 million for Q1 2025 and raised its full-year profit guidance to DKK 9.25-10.0 billion due to growth in core business areas, including net interest and fee income [3][4] - The company experienced an increase in mortgage and bank lending, resulting in expanded market positions [3] - Nykredit's investment portfolio income showed a positive trend despite market turbulence, and impairment charges remained low due to the financial robustness of customers [3] Financial Performance - Net interest income increased to DKK 3,039 million in Q1 2025 from DKK 3,011 million in Q1 2024, a change of DKK 28 million [4] - Net fee income rose to DKK 754 million in Q1 2025 from DKK 728 million in Q1 2024, an increase of DKK 26 million [4] - Wealth management income grew to DKK 713 million in Q1 2025 from DKK 668 million in Q1 2024, reflecting a DKK 45 million increase [4] - Total income decreased to DKK 5,434 million in Q1 2025 from DKK 6,012 million in Q1 2024, a decline of DKK 578 million [4] - Profit for the period fell to DKK 3,000 million in Q1 2025 from DKK 3,544 million in Q1 2024, a decrease of DKK 544 million [4] Lending and Market Position - Totalkredit's mortgage lending increased to DKK 921.8 billion at the end of March 2025 from DKK 879.7 billion at the end of March 2024 [3] - Nykredit Bank's lending after impairments rose to DKK 108.8 billion at the end of March 2025 from DKK 94.5 billion at the end of March 2024 [3] Strategic Developments - Nykredit launched a public tender offer to acquire Spar Nord Bank, aiming to create a strong, customer-owned alternative to the largest listed banks in Denmark [3] - The company raised the KundeKroner discount to 0.25% from 0.20% for new and existing customers, benefiting over 900,000 homeowners [3] Capital and Efficiency - Nykredit maintained a strong capital position with a Common Equity Tier 1 (CET1) capital ratio of 20.7% [6] - The cost/income ratio remained low at 30.8% in Q1 2025 [6]

Core Viewpoint - S&P Global Ratings upgraded Huhtamaki Oyj's long-term issuer credit rating to BBB- with a stable outlook, indicating the company's credit rating is now considered investment grade [1]. Financial Position - Huhtamaki has a solid financial position, with a net debt to adjusted EBITDA ratio of 2.0 at the end of March 2025, which is at the lower end of the target range of 2-3x [2]. Company Overview - Huhtamaki is a leading global provider of sustainable packaging solutions, with over 100 years of history and a strong Nordic heritage. The company operates in 36 countries with around 18,000 professionals across 102 locations [3]. - In 2024, Huhtamaki's net sales totaled EUR 4.1 billion, and the company is listed on the Nasdaq Helsinki with its head office located in Espoo, Finland [3].

Core Insights - CLIQ Group reported a significant decline in sales and customer metrics for Q1 2025, with total sales down 32% year-on-year to €50 million, primarily due to challenging market conditions [4][5] - The expected average lifetime value (LTV) of a customer decreased by 14% to €70, reflecting higher churn rates and a reduction in the number of paying customers to 0.8 million [4][11] - The company is undergoing a transformation program named "Fit For Future," aimed at improving cost efficiencies and productivity, which has been largely concluded but will continue to optimize operations [11][13] Financial Performance - Sales in North America fell by 24% and in Europe by 50%, while Latin America saw a slight increase of 4% [5] - Total customer acquisition costs decreased by 49% to €15 million, indicating a strategic shift towards profitability [5] - EBITDA before special items was €4 million, down 31% year-on-year, but the EBITDA margin remained stable at 7% [5][6] Cash Flow and Liquidity - As of March 31, 2025, the net cash position improved to €14 million from €12 million at the end of 2024 [6] - Operating free cash flow turned positive at €2 million, compared to a negative €4 million in Q1 2024, driven by a positive change in working capital [6] Customer Metrics - The number of unique paying customers decreased to 0.8 million from 1.1 million year-on-year, reflecting a focus on profitability over sales growth [11] - The lifetime value of the customer base declined by €35 million to €101 million, attributed to the reduction in customer numbers and lower expected LTV [11] Outlook - For 2025, CLIQ anticipates generating EBITDA between €10 million and €15 million, with expected sales ranging from €180 million to €220 million [12]

Core Insights - DEMIRE Deutsche Mittelstand Real Estate AG reported stable operating performance in Q1 2025, aligning with the Executive Board's expectations despite a reduced portfolio base [1] Financial Performance - Rental income decreased by 24.7% to EUR 14.0 million compared to EUR 18.6 million in Q1 2024, primarily due to a smaller portfolio [2] - Earnings before interest and taxes (EBIT) fell to EUR -3.4 million from EUR 4.8 million in the same period last year, largely due to market value adjustments of properties held for sale amounting to EUR -10.8 million [2] - FFO I (after taxes, before minority interests) totaled EUR 2.1 million, down from EUR 7.9 million in Q1 2024, reflecting the impact of the reduced property portfolio [3] Portfolio and Market Value - The market value of DEMIRE's portfolio decreased to approximately EUR 766.0 million after sales and value adjustments, down from EUR 779.3 million at the end of 2024 [4] - The net asset value (NAV) per share decreased by EUR 0.16 to EUR 2.29 in the reporting period, compared to EUR 2.45 at year-end 2024 [4] Letting Performance - The letting performance tripled to 25,500 square meters in Q1 2025, compared to 8,200 square meters in Q1 2024, marking the highest letting performance in a first quarter since 2022 [5] - The EPRA vacancy rate increased to 18.1% from 15.1% at year-end 2024, while the average remaining lease term (WALT) rose slightly to 4.8 years [5] Financial Stability - The net loan-to-value (LTV) ratio was stable at 41.5%, compared to 40.9% at year-end 2024, indicating a strengthened balance sheet [6] - Cash and cash equivalents amounted to EUR 46.2 million as of the reporting date [6] Guidance for 2025 - The Executive Board confirmed the guidance for 2025, expecting rental income between EUR 51.0 million and EUR 53.0 million, down from EUR 65.3 million in 2024, and FFO I between EUR 3.5 million and EUR 5.5 million, compared to EUR 26.2 million in 2024 [7][8]

Core Insights - Pharming Group N.V. reported a strong performance in the first quarter of 2025, with total revenues increasing by 42% to US$79.1 million compared to the same period in 2024, driven primarily by a 49% increase in RUCONEST® revenue [6][33][37] - The company has raised its full-year revenue guidance to between US$325 million and US$340 million, reflecting confidence in continued growth [2][37] - Pharming is making significant progress in expanding the availability of Joenja® for additional patients and is preparing for regulatory submissions in multiple markets [3][12][18] Financial Performance - Total revenues for Q1 2025 were US$79.1 million, up from US$55.6 million in Q1 2024, with RUCONEST® contributing US$68.6 million, a 49% increase [6][33] - Joenja® revenues reached US$10.5 million, a 9% increase compared to Q1 2024, with an 18% increase in unit sales volume [6][9][33] - Operating loss improved to US$7.0 million from US$16.3 million in Q1 2024, with adjusted operating profit of US$0.8 million when excluding non-recurring expenses related to the Abliva acquisition [35][36] Product Developments - Joenja® was launched in England and Wales in April 2025 following a positive reimbursement decision from NICE, and the company is preparing to file for U.S. FDA approval for pediatric use in Q3 2025 [3][12][17] - The company is advancing its pipeline, including ongoing clinical trials for leniolisib in primary immunodeficiencies and KL1333 for mitochondrial diseases [4][21][25] Market Contributions - The U.S. market accounted for 97% of total revenues in Q1 2025, highlighting the strong demand for RUCONEST® and Joenja® in this region [7][8] - The company has identified approximately 250 APDS patients in the U.S. eligible for Joenja®, with ongoing efforts to find and transition more patients to paid therapy [11][13][14] Strategic Initiatives - Pharming completed the acquisition of Abliva AB for approximately US$66.1 million, which is expected to enhance future growth prospects [23][24] - The company is optimizing capital allocation with a target of reducing general and administrative expenses by 15% or US$10 million annually [2][6]

Core Insights - Zealand Pharma has reported significant progress in its clinical pipeline and has established a transformative partnership with Roche for petrelintide, positioning the company for accelerated growth [1][3]. Financial Performance - For Q1 2025, Zealand Pharma reported revenue of DKK 8.1 million, a decrease from DKK 15.1 million in Q1 2024 [4]. - Operating expenses increased to DKK 393.1 million from DKK 266.3 million year-over-year [4]. - The operating result was a loss of DKK 385.5 million compared to a loss of DKK 255.8 million in the same quarter last year [4]. - The net financial items improved to DKK 70.3 million from DKK 25.8 million [4]. - The cash position as of March 31, 2025, was DKK 8,544.5 million, down from DKK 9,022.0 million at the end of 2024 [4]. Strategic Developments - Zealand Pharma entered a collaboration and license agreement with Roche to co-develop and co-commercialize petrelintide, sharing profits and losses on a 50/50 basis [4][5]. - The partnership aims to establish a leading amylin-based franchise for weight management and related indications [5]. - Zealand Pharma completed enrollment in the Phase 2 ZUPREME-1 trial for petrelintide three months after initiation [5][9]. Corporate Updates - Utpal Singh was appointed as Chief Scientific Officer to lead the next wave of innovative medicines [5][10]. - Steven R. Smith was appointed as Senior Global Medical Advisor in Obesity to support obesity research and clinical development programs [8]. Upcoming Milestones - Zealand Pharma expects to submit a Marketing Authorization Application for glepaglutide in the second half of 2025 and initiate a Phase 3 clinical trial [12]. - The company anticipates reporting topline results from the Phase 2 ZUPREME-1 trial in the first half of 2026 [14]. - Zealand Pharma plans to host a Capital Markets Day in London on December 11, 2025 [17]. Financial Guidance - The financial guidance for 2025 remains unchanged, with net operating expenses expected to be between DKK 2,000 million and DKK 2,500 million [18][19].